Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report - Scorecard - MDSpire
Advertisement
Depigmentation resembling vitiligo after neoadjuvant chemotherapy and pembrolizumab in early-stage triple-negative breast cancer: a case study
Clinical Scorecard: Depigmentation resembling vitiligo after neoadjuvant chemotherapy and pembrolizumab in early-stage triple-negative breast cancer: a case study
At a Glance
Category
Detail
Condition
Triple-negative breast cancer (TNBC)
Key Mechanisms
Combination of immune checkpoint inhibitors with neoadjuvant chemotherapy
Target Population
Patients with early-stage triple-negative breast cancer
Care Setting
Oncology treatment center
Key Highlights
Patient developed vitiligo-like depigmentation during pembrolizumab maintenance therapy.
Pathological complete response achieved after neoadjuvant chemotherapy with pembrolizumab.
Vitiligo-like changes were asymptomatic and did not interrupt immunotherapy.
Recognition of this manifestation may help avoid unnecessary treatment interruptions.
Further reports are needed to clarify the clinical significance of immune-related depigmentation.
Guideline-Based Recommendations
Diagnosis
Histopathological examination confirms invasive breast carcinoma.
Immunohistochemical analysis shows negativity for ER and PR, and absence of HER2 overexpression.
Management
Neoadjuvant chemotherapy with taxane and carboplatin in combination with pembrolizumab.
Monitoring & Follow-up
Serial imaging assessments to evaluate tumor response during treatment.
Risks
Potential for immune-related adverse events, including cutaneous manifestations.
Patient & Prescribing Data
Female patients with early-stage triple-negative breast cancer.
Pembrolizumab combined with chemotherapy improves pathological response rates.
Clinical Best Practices
Monitor for immune-related adverse events during immunotherapy.
Educate patients on potential cutaneous manifestations of treatment.
